SanBio Company Limited (4592.T) stock price, financials & research

Regular session · JST · Market data may be delayed.

Company profile

SanBio Company Limited is dedicated to the creation, production, and sale of regenerative cell therapies, primarily concentrated on disorders of the central nervous system. A central component of their portfolio is SB623, a treatment that has completed Phase 2 clinical trials in both the United States and Japan for traumatic brain injury. Beyond this, their comprehensive research pipeline explores the broader potential of SB623 for conditions such as ischemic and hemorrhagic strokes, age-related macular degeneration, retinitis pigmentosa, spinal cord injury, Parkinson's disease, and Alzheimer's disease. The company's development efforts also encompass other innovative treatments: SB618 for peripheral nerve damage, SB308 for muscular dystrophy, MSC1 for cancer, and MSC2 for inflammatory diseases and optic neuritis. Founded in 2001, SanBio maintains its corporate headquarters in Tokyo, Japan.

Industry: Biotechnology
Sector: Healthcare
Headquarters: JP
CEO: Keita Mori
Listed since: Apr 8, 2015
Employees: 33

Market position

Day range

Current ¥1,004

¥995¥1,030

52-week range

Current ¥1,004

¥874¥3,990

Open: ¥1,016
Previous close: ¥1,010
Volume: 626.7K; 0.53× average
Average volume: 1.19M; Average daily volume
Market cap: 78.35B JPY
Beta: 0.28; Market reference 1
50-day average: ¥1,013.42; -0.93% below average
200-day average: ¥1,685.51; -40.43% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

P/E (TTM): -23.94×
P/B (TTM): 6.18×
P/S (TTM): 0×
Dividend yield: 0.00%

Profitability & efficiency

Gross margin: 0.00%
Operating margin: 0.00%
Net margin: 0.00%

Financial health

Debt / equity: 0.09×

Financial statements

Income trends

Operating income

−3.79B JPY-7.93%

Net income

−3.84B JPY-33.29%

Metric (JPY)	FY2026	FY2025	FY2024	FY2023	FY2022
Cost of goods sold	8.05M JPY	9.37M JPY	14.5M JPY	24.62M JPY	132.47M JPY
Gross profit	−8.05M JPY	−9.37M JPY	−14.5M JPY	−24.62M JPY	−132.47M JPY
Research and development	2.68B JPY	2.36B JPY	2.85B JPY	6.12B JPY	4.96B JPY
Selling, general, and administrative	1.11B JPY	1.15B JPY	1.68B JPY	1.76B JPY	1.53B JPY
Operating expenses	3.79B JPY	3.51B JPY	4.53B JPY	7.87B JPY	6.49B JPY
Interest income	6.47M JPY	2.4M JPY	2.47M JPY	4.01M JPY	2.24M JPY
Interest expense	81.06M JPY	18.94M JPY	25.81M JPY	56.24M JPY	54.8M JPY
Depreciation and amortization	8.05M JPY	9.37M JPY	14.5M JPY	24.62M JPY	132.47M JPY
Operating income	−3.79B JPY	−3.52B JPY	−4.54B JPY	−7.9B JPY	−6.62B JPY
Net income	−3.84B JPY	−2.88B JPY	−2.64B JPY	−5.56B JPY	−4.68B JPY